Competitive Outlook on HCV: What to Know and Expect in R&D and Business Development

BioSeeker announces the release of a new report entitled "Competitive Outlook on HCV: What to Know and Expect in R&D and Business Development". BioSeeker has in this report taken a fresh look on both the current world status of R&D and business development in HCV. Our research and analysis is built on more than 150 companies from over 18 different countries and include more than 160 pipline drugs in development for HCV.

(PRWEB) September 28, 2004 -- BioSeeker announces the release of a new report entitled "Competitive Outlook on HCV: What to Know and Expect in R&D and Business Development".

The competitive business environment for the pharmaceutical market of chronic hepatitis C virus (HCV) infection is fierce and changing. The entry of Hoffmann-La Roche into this $3 billion market, previously dominated by Schering-Plough, has certainly paved the way and will make life easier for other HCV drug developing companies. Competition is healthy, and market dominance by one big pharma provides far fewer business opportunities compared to two companies fighting to be the world leader.

The race is on and due to the limitations of current treatment for chronic hepatitis C virus infection, a lot of R&D activities are spent on novel therapeutic strategies targeting events specific to viral replication. A number of newer therapies, including protease and helicase inhibitors, ribozymes, antisense therapies, and therapeutic vaccines, are in preclinical or clinical development and may significantly enhance existing therapeutic options for the future.

BioSeeker has in this report taken a fresh look on both the current world status of R&D and business development in HCV. Our research and analysis is built on more than 150 companies from over 18 different countries and include more than 160 pipline drugs in development for HCV.

We give you an up to date outline of the HCV competitive landscape, involving 66 selected collaborations divided into 7 major clusters of companies, whereof six are interconnected and one cluster stands alone. Find out key data on each cluster, such as Type of Collaboration (9 classes), R&D Focus, Number of Drugs in Development, Competitive Edge etc. BioSeeker's competitive analysis sheds light and increases understanding of alliances that future partners are involved in, so that you can minimize the risk that competitors can gain information about what you are planning to do.

BioSeeker's HCV R&D analysis thoroughly discusses drug and vaccine development world wide. The analysis covers more than 108 pipeline drugs, ranging from pre-clinical to phase III. Key points in the analysis are to deduce trends in HCV drug development, evaluate all major drug targets and outline country by country efforts in HCV. The analysis also addresses the issue of what demands are raised on new HCV drugs and how the industry gradually will move over from interferon to small molecular drugs and combination therapies thereof. Special emphasis is put on linking analysis with concrete R&D projects through high value tables, in order to facilitate further research.

This report has been written for people in business development, competitive intelligence, and for R&D project responsibles in HCV. We do also believe that this report is suitable for CEOs, especially in smaller sized companies.

For more information about this report, please visit BioSeeker's website at http://www.bioseeker.com/?report=bsgcohcv
###